EPIOXA HD/EPIOXA KIT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for EPIOXA HD/EPIOXA KIT (EPIOXA HD/EPIOXA KIT).
Oxaliplatin undergoes nonenzymatic biotransformation to active platinum derivatives that form inter- and intrastrand crosslinks in DNA, inhibiting DNA replication and transcription.
| Metabolism | Nonenzymatic biotransformation; extensive tissue distribution; mainly eliminated via renal excretion. |
| Excretion | Primarily renal excretion; 70-80% of the dose is eliminated unchanged in urine within 48 hours; biliary/fecal excretion accounts for less than 10%. |
| Half-life | Terminal elimination half-life is approximately 0.7-1.1 hours (42-66 minutes) in patients with normal renal function; prolonged in renal impairment, necessitating dose adjustment. |
| Protein binding | Low protein binding; approximately 10-20% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is approximately 0.1-0.25 L/kg, indicating distribution primarily in extracellular fluid; clinically, this suggests limited tissue penetration. |
| Bioavailability | Oral bioavailability is negligible (<1%); therefore, the drug is administered exclusively via intravenous route. |
| Onset of Action | Intravenous administration: onset of antimicrobial effect is immediate upon achieving therapeutic plasma concentrations; clinical response typically observed within 24-48 hours. |
| Duration of Action | Duration of antimicrobial effect is limited by rapid clearance; dosing intervals are typically every 8-12 hours to maintain therapeutic levels; clinical duration depends on infection severity and pathogen susceptibility. |
EPIOXA HD: 100 mg/m² IV over 2 hours every 2 weeks. EPIOXA KIT: 100 mg/m² IV over 2 hours every 2 weeks.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | CrCl <30 mL/min: contraindicated. CrCl 30-50 mL/min: reduce dose to 75 mg/m². CrCl >50 mL/min: no adjustment. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: reduce dose to 75 mg/m². Child-Pugh C: not recommended. |
| Pediatric use | Safety and efficacy not established in pediatric patients; use not recommended. |
| Geriatric use | No specific dose adjustment; monitor renal function and toxicity closely. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for EPIOXA HD/EPIOXA KIT (EPIOXA HD/EPIOXA KIT).
| Breastfeeding | Epirubicin is excreted in human breast milk. The M/P ratio is not determined. Breastfeeding is contraindicated during therapy and for at least 1 month after last dose due to potential for severe adverse effects in the nursing infant (e.g., immunosuppression, neutropenia, cardiotoxicity). |
| Teratogenic Risk | EPIOXA HD/EPIOXA KIT contains epirubicin, an anthracycline cytotoxic agent classified as FDA Pregnancy Category D. First trimester: high risk of embryotoxicity and teratogenicity; use contraindicated due to potential for spontaneous abortion and major congenital malformations. Second and third trimesters: risk of fetal myelosuppression, intrauterine growth restriction (IUGR), and premature delivery. Avoid use unless maternal benefit outweighs fetal risk. |
■ FDA Black Box Warning
Anaphylactic reactions have been reported and may occur within minutes of administration. Epinephrine, corticosteroids, and antihistamines should be available.
| Serious Effects |
History of severe hypersensitivity to oxaliplatin or other platinum compounds; severe renal impairment (CrCl <30 mL/min).
| Precautions | Peripheral neuropathy, acute and chronic; pulmonary fibrosis; hepatic toxicity; renal impairment; pregnancy category D; myelosuppression; extravasation. |
Loading safety data…
| Fetal Monitoring | Maternal: Complete blood count (CBC) with differential, liver function tests (LFTs), serum creatinine, left ventricular ejection fraction (LVEF) via echocardiogram or MUGA scan, and assessment for signs of infection or bleeding. Fetal: Serial ultrasound assessments for fetal growth, amniotic fluid volume, and signs of fetal distress (e.g., non-stress test, biophysical profile) if pregnancy continuation elected. |
| Fertility Effects | Epirubicin may cause irreversible ovarian failure in premenopausal women, leading to premature menopause and infertility. It can also cause testicular damage in males, potentially resulting in azoospermia or oligospermia. Fertility preservation counseling (e.g., oocyte or sperm cryopreservation) should be offered before initiation. |